Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants.
Health sciences
Immune response
Immunology
Virology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
19 Aug 2022
19 Aug 2022
Historique:
received:
22
04
2022
revised:
16
06
2022
accepted:
06
07
2022
pubmed:
19
7
2022
medline:
19
7
2022
entrez:
18
7
2022
Statut:
ppublish
Résumé
Cell-mediated immunity may contribute to providing protection against SARS-CoV-2 and its variants of concern (VOC). We developed COH04S1, a synthetic multiantigen modified vaccinia Ankara (MVA)-based COVID-19 vaccine that stimulated potent spike (S) and nucleocapsid (N) antigen-specific humoral and cellular immunity in a phase 1 clinical trial in healthy adults. Here, we show that individuals vaccinated with COH04S1 or mRNA vaccine BNT162b2 maintain robust cross-reactive cellular immunity for six or more months post-vaccination. Although neutralizing antibodies induced in COH04S1- and BNT162b2-vaccinees showed reduced activity against Delta and Omicron variants compared to ancestral SARS-CoV-2, S-specific T cells elicited in both COH04S1- and BNT162b2-vaccinees and N-specific T cells elicited in COH04S1-vaccinees demonstrated potent and equivalent cross-reactivity against ancestral SARS-CoV-2 and the major VOC. These results suggest that vaccine-induced T cells to S and N antigens may constitute a critical second line of defense to provide long-term protection against SARS-CoV-2 VOC.
Identifiants
pubmed: 35846380
doi: 10.1016/j.isci.2022.104745
pii: S2589-0042(22)01017-3
pmc: PMC9272674
doi:
Types de publication
Journal Article
Langues
eng
Pagination
104745Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
While unknown whether the publication of this report will aid in receiving grants and contracts, it is possible that this publication will be of benefit to the City of Hope (COH). COH had no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the article. DJD and FW are co-inventors on a patent application covering the design and construction of the synthetic MVA platform (PCT/US2021/016,247). DJD, FW, and FC are co-inventors on a patent application covering the development of a COVID-19 vaccine (PCT/US2021/032,821). DJD is a consultant for GeoVax. All other authors declare no competing interests. GeoVax Labs Inc. has taken a worldwide exclusive license for COH04S1 under the name of GEO-CM04S1.
Références
Sci Adv. 2022 Aug 5;8(31):eabp9770
pubmed: 35921414
Nat Microbiol. 2022 Jul;7(7):974-985
pubmed: 35681012
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145
pubmed: 35085224
Immunity. 2020 Nov 17;53(5):1095-1107.e3
pubmed: 33128877
Cell Rep Med. 2021 Jul 20;2(7):100355
pubmed: 34230917
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Lancet Microbe. 2022 Jan;3(1):e21-e31
pubmed: 34778853
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Lancet Respir Med. 2022 Jul;10(7):689-699
pubmed: 35468336
Nature. 2022 Mar;603(7901):493-496
pubmed: 35102312
iScience. 2022 Jun 17;25(6):104457
pubmed: 35634578
Geroscience. 2021 Oct;43(5):2321-2331
pubmed: 34633612
Nat Med. 2022 Mar;28(3):486-489
pubmed: 35051989
Transplant Cell Ther. 2022 May;28(5):279.e1-279.e4
pubmed: 35218998
Proc Natl Acad Sci U S A. 2022 May 17;119(20):e2118312119
pubmed: 35561224
Cell. 2022 Mar 17;185(6):1041-1051.e6
pubmed: 35202566
Cell Mol Immunol. 2021 Oct;18(10):2307-2312
pubmed: 34471260
N Engl J Med. 2022 Apr 14;386(15):1477-1479
pubmed: 35263515
Cell Mol Immunol. 2021 Aug;18(8):2040-2041
pubmed: 34267334
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
Front Immunol. 2021 Jul 12;12:687449
pubmed: 34322120
Cell Rep. 2021 Feb 9;34(6):108728
pubmed: 33516277
N Engl J Med. 2022 Jun 23;386(25):2433-2435
pubmed: 35613039
Vaccines (Basel). 2021 Nov 10;9(11):
pubmed: 34835238
Nat Commun. 2022 May 13;13(1):2670
pubmed: 35562366
J Immunol. 2021 Jul 15;207(2):376-379
pubmed: 34193597
Viruses. 2022 Jun 18;14(6):
pubmed: 35746806
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
Front Immunol. 2022 Feb 22;13:835830
pubmed: 35273611
Nat Med. 2022 Mar;28(3):490-495
pubmed: 35046573
NPJ Vaccines. 2022 Jan 21;7(1):7
pubmed: 35064109
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Lancet Microbe. 2022 Apr;3(4):e252-e264
pubmed: 35287430
Nat Commun. 2020 Nov 30;11(1):6121
pubmed: 33257686
Science. 2022 Feb 11;375(6581):678-680
pubmed: 35040667
Viruses. 2020 May 06;12(5):
pubmed: 32384820
Nat Med. 2022 Mar;28(3):472-476
pubmed: 35042228
Cell Rep. 2021 Sep 7;36(10):109664
pubmed: 34450033
Cell. 2022 Mar 3;185(5):896-915.e19
pubmed: 35180381